Business Wire

NOMIOS-GROUP

2.3.2023 06:33:06 CET | Business Wire | Press release

Share
Nomios Group Expands in Southern Europe with the Leading Italian Cybersecurity Expert Aditinet

Nomios Group, a leading European provider of cybersecurity services and solutions, announced today that it has completed the acquisition of a majority stake in Aditinet, a prominent cybersecurity company in the Italian market. The acquisition strengthens Nomios’ European position as one of the leading cybersecurity service companies.

“This acquisition marks an important step in Nomios’ continued growth and success, and we see many benefits in terms of a shared vendor portfolio, customer relationship, and service offerings. Not only does the acquisition of Aditinet provide the Nomios Group with a significant expertise and strong customer base in Italy, but it also allows us to add new services such as ethical hacking to our portfolio” explained Sébastien Kher, CEO of Nomios Group.

With the addition of Aditinet, the Nomios Group annual revenue grows to EUR 400M, and its consolidated headcount grows to over 600 FTEs throughout its seven European markets. The current CEO and Founder (Paolo Marsella) and CFO (Alberto Mez) will remain minority shareholders and will continue to manage the company and will lead the integration within the Nomios Group.

“Becoming part of Nomios is the ideal next step in realising Aditinet’s vision of making IT and the cloud the most secure environment for our customers and in further consolidating our relationships with critical vendors” said Paolo Marsella, CEO of Aditinet. “Nomios will provide European scale and expertise to further accelerate our growth in the Italian market. We look forward to immediately take advantage of Nomios’ famous SOC capabilities to help monitor our customer’s security perimeters and rely on their many references in SASE. We see a lot of talks about these technologies in the market, and our new Nomios colleagues have already proven that they can deliver in both respects”.

About Nomios Group

Nomios is a leading European provider of cybersecurity and secure networking solutions and services and has a broad customer base in highly diversified sectors. In 19 years, Nomios has grown into an organisation with more than 20 offices in seven European countries and has continuously expanded its own professional services, managed services, support and SOC offering. Nomios has the most experienced, loyal and highly certified pool of engineers in its industry, as recognised by many third-party studies, and has strategic partnerships with leading technology providers, including Palo Alto Networks, Juniper Networks, Cisco, Fortinet, F5, and others. In January 2019, funds advised by IK Partners, a leading Pan-European private equity firm, acquired a majority stake in Nomios Group.

About Aditinet

Founded in 2004, Aditinet is an Italian system integration and professional services company specialising in cybersecurity. With an annual revenue of EUR 40 million, Aditinet is among the most recognised players in the Italian cybersecurity industry with best-in- class certifications with Palo Alto Networks (Diamond) and F5 (Platinum) among other highly ranked vendor partnerships. Aditinet has two main offices in Italy, namely in Rome and Milan. Aditinet serves over 150 customers, which include several Italian national banks, utility providers, universities, manufacturing companies and ministries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006051/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye